TBTemesgen Baylie

Temesgen Baylie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Temesgen Baylie has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Mamaru Getinet

    Department of Biomedical Sciences, School of Medicine, Debre Markos University, Debre Markos, Ethiopia

    4 shared publications
  • Mohammed Jemal

    Department of Biomedical Sciences, School of Medicine, Debre Markos University, Debre Markos, Ethiopia

    4 shared publications
  • Adane Adugna

    Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia

    3 shared publications
  • Adane Adugna

    Department of Medical Laboratory Science, College of Medicine and Health Sciences, Debre Markos University, Debre Markos, Ethiopia

    3 shared publications
  • Desalegn Abebaw

    Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia

    3 shared publications
  • Kibur Hunie Tesfa

    Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

    3 shared publications

Latest Publications

  • Open Access

    Mechanistic roles of oxidized low density lipoprotein receptor 1(LOX-1) in fibrotic diseases and its diagnostic and therapeutic implications

    by Melkamu Tilahun, Adane Adugna, Temesgen Baylie, Nibret Abebaw Yeneneh, Megbar Dessalegn, Haile Amha, Etsubdink Dessalew Abawa, Yeshimareg Shita Mekete, Worku Abie Liyew, Baye Ashenef, et al.

  • Open Access

    Epigenetic and Metabolic Changes That Drive Trained Immunity in Response to Microbes and Vaccines

    by Desalegn Abebaw, Aytenew Atnaf, Bantayehu Addis Tegegne, Abebe Fenta, Bantegzie Selabat, Temesgen Baylie, Yonatan Kindie, Zigale Hibstu Teffera, Mekuriaw Belayneh, Mohammed Jemal, et al.

    Trained immunity is a form of innate immune memory in which initial exposure to microbial components or vaccines leads to long‐lasting functional reprogramming of innate immune cells through epigenetic and metabolic changes. Unlike adaptive immunity, it does not rely on B or T lymphocytes and provides broad, nonspecific protection against various pathogens. This phenomenon has been observed across a range of immune cells, including monocytes, macrophages, neutrophils, NK cells and even γδ T‐cells, as well as at the level of haematopoietic stem and progenitor cells (HSPCs). Key inducers include microbial products (e.g., β‐glucan, BCG and MMR vaccines), metabolic byproducts (e.g., mevalonate and lactate) and cytokines such as IL‐1β. These agents activate signalling pathways such as the Akt/mTOR/HIF‐1α pathway and lead to chromatin remodelling via histone modifications such as H3K4me3 and H3K9me3. Immunometabolism plays a pivotal role, with trained cells shifting toward glycolysis, glutaminolysis and cholesterol synthesis. Lactate and fumarate further link metabolism to epigenetic remodelling. Notably, trained immunity can be protective in infectious diseases and beneficial in noninfectious contexts, such as cancer immunotherapy and autoimmune regulation. This review provides a comprehensive overview of the cellular, epigenetic and metabolic mechanisms underlying trained immunity, highlighting how innate immune cells acquire memory‐like properties independent of adaptive immunity. This study also provides insights into the therapeutic potential of leveraging trained immunity for vaccine development, infection control and immunomodulation in noninfectious diseases.

  • Open Access

    Telomerase and chronic inflammation as central molecular links in aging

    by Temesgen Baylie, Endalkachew Gugsa, Mohammed Jemal, Gelagay Baye, Mamaru Getinet, Gashaw Azanaw Amare, Adane Adugna, Desalegn Abebaw, Zigale Hibstu, Bantayehu Addis Tegegne, et al.


  • Open Access

    The role of telomere and telomerase in cancer and novel therapeutic target: narrative review

    by Temesgen Baylie, Mohammed Jemal, Gelagay Baye, Mamaru Getinet, Gashaw Azanaw Amare, Adane Adugna, Desalegn Abebaw, Zigale Hibstu, Bantayehu Addis Tegegne, Endalkachew Gugsa, et al.

    Telomeres are dynamic complexes at the ends of chromosomes that are made up of protective proteins and tandem repeating DNA sequences. In the large majority of cancer cells, telomere length is maintained by telomerase, an enzyme that elongates telomeres. Telomerase activation is seen in the majority of cancer, which permits uncontrol cell proliferation. About 90% of human malignancies show telomere dysfunction and telomerase reactivation; as a result, telomerase activation plays a special role as a practically universal stage on the way to malignancy. This review understands the structural and functional of telomere and telomerase, mechanisms of telomerase activation in oncogenesis, biomarkers and therapeutic targets. Therapeutic strategies targeting telomerase, including antisense oligonucleotides, G-quadruplex stabilizers, immunotherapy, small-molecule inhibitors, gene therapy, Telomerase-Responsive Drug Release System, have shown promise in preclinical and clinical settings. Advances in telomere biology not only illuminate the complex interplay between telomeres, telomerase, and cancer progression but also open avenues for innovative, targeted cancer therapies.


  • Open Access

    QTc Interval and Its Associated Factors in Patient With Type 2 Diabetic Mellites

    by Deresse Sinamaw Asmare, Tadegew Adane Abebe, Baye Ashenef, Temesgen Baylie, Yeshimareg Shita

    Introduction: There is a notable link between diabetes mellitus (DM) and cardiovascular diseases (CVDs), particularly abnormal ventricular repolarization marked by a prolonged QT interval, which significantly contributes to morbidity and mortality in diabetic patients. However, no studies have been conducted in Ethiopia regarding prolonged QT intervals in Type 2 diabetic patients. Therefore, this study is aimed at examining the prevalence of prolonged QT intervals and the associated factors among Type 2 diabetic patients in selected referral hospitals in the Amhara Region, Ethiopia. Methods: A cross‐sectional study was conducted from May 30, 2024, to September 30, 2024, involving 300 participants. Participants were selected using systematic sampling. Data were collected through questionnaires, anthropometric measurements, blood pressure readings, and lipid profile analyses. QTc interval was determined by using digital electrocardiographic machine. The study utilized bivariable and multivariable logistic regression models to identify factors associated with prolonged QT intervals. Results: The average QT interval was 420 ± 4.8 ms, with 45.6% of patients exhibiting prolonged QT intervals. Multivariable logistic regression analysis identified significant associations between prolonged QT intervals and factors such as age (AOR 1.11, 95% CI: 1.01–2.42), duration of diabetes (AOR 2.52, 95% CI: 1.12–5.31), body mass index (AOR 1.65, 95% CI: 1.21–3.44), fasting blood sugar (AOR 2.21, 95% CI: 1.12–6.21), sulfonylureas drug treatment (AOR 2.42, 95% CI: 1.21–5.94), HbA1c (AOR 2.78, 95% CI: 1.07–6.48), and total cholesterol (AOR 6.21, 95% CI: 4.25–11.25). Conclusion: This study highlights the significant prevalence of prolonged QT intervals among Type 2 diabetic patients. Several factors significantly contribute to the likelihood of prolonged QT intervals in Type 2 diabetic patients. These include older age, longer duration of diabetes, higher BMI, elevated fasting blood sugar levels, use of sulfonylureas, higher HbA1c levels, and elevated total cholesterol. This significant finding underscores the importance of regular cardiovascular monitoring and effective management strategies to mitigate the risks associated with prolonged QT intervals in this population.

  • Open Access

    Evaluation of antioxidant and antihyperglycemic effects Dovyalis Abyssinica (A. Rich)

    by Temesgen Baylie, Wuhabie Tsega, Mamaru Getinet, Desalegn Abebaw, Gashaw Azanaw, Adane Adugna, Mohammed Jemal


  • Open Access

    The role of miRNAs as biomarkers in breast cancer

    by Temesgen Baylie, Mulugeta Kasaw, Mamaru Getinet, Gedefaw Getie, Mohammed Jemal, Amare Nigatu, Hassen Ahmed, Mihiret Bogale

    Breast cancer (BC) is the second most common cause of deaths reported in women worldwide, and therefore there is a need to identify BC patients at an early stage as timely diagnosis would help in effective management and appropriate monitoring of patients. This will allow for proper patient monitoring and effective care. However, the absence of a particular biomarker for BC early diagnosis and surveillance makes it difficult to accomplish these objectives. miRNAs have been identified as master regulators of the molecular pathways that are emphasized in various tumors and that lead to the advancement of malignancies. Small, non-coding RNA molecules known as miRNAs target particular mRNAs to control the expression of genes. miRNAs dysregulation has been linked to the start and development of a number of human malignancies, including BC, since there is compelling evidence that miRNAs can function as tumor suppressor genes or oncogenes. The current level of knowledge on the role of miRNAs in BC diagnosis, prognosis, and treatment is presented in this review. miRNAs can regulate the tumorigenesis of BC through targeting PI3K pathway and can be used as prognostic or diagnostic biomarkers for BC therapy. Some miRNAs, like miR-9, miR-10b, and miR-17-5p, are becoming known as biomarkers of BC for diagnosis, prognosis, and therapeutic outcome prediction. Other miRNAs, like miR-30c, miR-187, and miR-339-5p, play significant roles in the regulation of hallmark functions of BC, including invasion, metastasis, proliferation, resting death, apoptosis, and genomic instability. Other miRNAs, such as miR-155 and miR-210, are circulating in bodily fluids and are therefore of interest as novel, conveniently accessible, reasonably priced, non-invasive methods for the customized care of patients with BC.


  • Open Access

    Effect of Ketogenic Diet on Obesity and Other Metabolic Disorders: Narrative Review

    by Temesgen Baylie, Tiget Ayelgn, Markeshaw Tiruneh, Kibur Hunie Tesfa

    Obesity is defined as an abnormal or excessive accumulation of fat that increases the burden of different chronic diseases in the population. It has reached epidemic proportions and is a major risk factor for a variety of diseases, including hypertension, cardiovascular disease, type 2 diabetes, dyslipidaemia, atherosclerosis, and some malignancies. Weight gain is a result of excessive energy intake compared to energy expenditure (energy loss from metabolism and physical exercise). A ketogenic diet has a more useful effect on obesity than other diets. A ketogenic diet is a low-carbohydrate, high-fat, moderate-protein diet that induces the production of ketone bodies by mimicking the breakdown of a fasting state. The mechanism behind the ketogenic diet is still unknown, although it obviously helps people with obesity lose weight. Several pathways for the ketogenic diet effect on weight loss have been hypothesized by researchers, including reduced appetite due to effects on appetite control hormones and a possible direct appetite suppressant action of ketone bodies; reduced lipogenesis and increased lipolysis; greater metabolic efficiency; and increased metabolic costs.


  • Open Access

    Overweight and Obesity Among People Living With HIV on Dolutegravir‐ and Efavirenz‐Based Therapies: A Comparative Cross‐Sectional Study

    by Mohammed Jemal, Adane Adugna, Mamaru Getinet, Temesgen Baylie, Nuredin Chura Waritu

    Background: Overweight and obesity have arisen as major public health challenges, affecting not just the general population but also people living with human immunodeficiency virus (HIV) (PLWH). Obesity and being overweight are both risk factors for heart disease and other related complications. However, little is known in our setting. As a result, this study was conducted to evaluate the prevalence of overweight and obesity and its associated factors among PLWH on dolutegravir (DTG)‐ and efavirenz (EFV)‐based therapies.Methods: An institution‐based comparative cross‐sectional study was carried out from June 30, 2021, to August 30, 2021. We purposively recruited 128 participants who have been on DTG (n = 64)‐ and EFV (n = 64)‐based regimens for ≥ 6 months. Demographic, anthropometric, laboratory, and clinical data were collected using a structured questionnaire. The data were entered into EpiData Version 4.6 and analyzed using SPSS Version 26.0. Multivariable logistic regression was utilized to identify the factors that are associated with being overweight or obese, and the significance level was set at p < 0.05.Result: The prevalence of overweight and obesity was 28.1% in the DTG‐prescribed participants and 15.6% in the EFV‐prescribed participants. Age ≥ 40 years (adjusted odd ratio (AOR) = 3.86; 95% confidence interval (CI): 1.08–13.73; and p = 0.037), cluster of differentiation 4 (CD4) T‐cell counts ≥ 500 cells/mm3 (AOR = 2.95; 95% CI: 1.01–8.59; and p = 0.029), and insufficient physical activity (AOR = 4.6; 95% CI: 1.53–13.84; and p = 0.007) were predictors of overweight and obesity.Conclusion: Overweight and obesity are not uncommon among PLWH on ART. While the difference was statistically insignificant, the prevalence of overweight and obesity was higher in patients treated with DTG compared with those treated with EFV. Older age, higher CD4 cell counts, and insufficient physical activity were associated with overweight and obesity. As a result, healthcare providers must understand the health implications of obesity and consider incorporating targeted weight control programs into standard HIV treatment.


  • Open Access

    Anti-Diabetic Effects of the 80% Methanolic Extract of Datura Stramonium Linn (Solanaceae) Leaves in Streptozotocin- Induced Diabetic Mice

    by Temesgen Baylie, Assefa Kebad, Tiget Ayelgn, Markeshaw Tiruneh, Kibur Hunie Tesfa

    Background: Managing diabetes mellitus with currently available drugs is costly, and the chances of side effects are high, leading to further studies for new and better medications from plant sources with the affordable and lower side effects. This study aimed to evaluate the anti-diabetic effects of Datura stramonium Linn (Solanaceae) Leaves Extract in Streptozotocin- Induced Diabetic Mice. Methods: Male Swiss albino mice were induced into diabetes using 150mg/kg of STZ. Mice were allocated randomly into six groups, five mice per group. Group I was a normal control, Group II was Diabetic negative control, group III was Diabetic positive control, Group IV–VI were Diabetic Mice that treated with extract (100, 200 and 400 mg/kg) for 14 days. The FBG measurements were done on 0, 7th, and 14th days of treatment. After 14th day of treatment the mice were anesthetized with diethyl ether. Then, blood was drawn by cardiac puncture to assess TC, TG, LDL-C, and HDL-C. The antioxidant activity of the extract was determined using a DPPH assay. The data were entered into Epi-Data version 4.6, exported to SPSS version 26.0, and analyzed using a one-way ANOVA followed by a Tukey post hoc test. P < 0.05 was considered statistically significant. Results: The extract of D. stramonium reduced the FBG level by 19.71%, 30.27%, 40.95%, and 45.67%, respectively, for D. stramonium 100, 200, 400, and GLC 5 mg/kg on the 14th day of treatment. Diabetic mice treated with D. stramonium for 14 days showed a significant decrease in serum TC, LDL, and serum TG and a significant increase in body weight, and HDL level as compared to diabetic negative control. Antioxidant activities of the leaves extract were comparable to ascorbic acid with an IC50 of 172.79 μg/mL. Conclusion: These findings revealed that the D. stramonium leaves extract possesses significant Anti-diabetic activities.